ArticleOrphanet journal of rare diseases2026
Impaired mitochondrial morphology and respiratory dysfunction in human induced pluripotent stem cells with mitochondrial tRNA mutations (m.3243A>G and m.14739G>A).
Article in Orphanet journal of rare diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundMitochondrial DNA (mtDNA) mutations contribute to respiratory dysfunction and cause mitochondrial diseases. The pathologies of these multisystemic inherited diseases are poorly understood. Mutations in the mitochondrial tRNA gene are one of the most frequent mtDNA mutations and are associated with various clinical symptoms such as diabetes mellitus, hearing loss, cardiomyopathy, exercise intolerance, and found in patients with mitochondrial disorders. Human induced pluripotent stem cells (hiPSCs), generated by reprogramming patient-specific somatic cells are recognized as useful tools for disease modeling and serve to better understand the multisystemic pathologies associated with mitochondrial tRNA mutations.
methodshiPSCs were generated from control BJ and two fibroblast lines with mitochondrial tRNA mutations using non-modified reprogramming and immune evasion mRNAs and microRNAs. Expression of hiPSC-associated intracellular and cell surface markers were identified by immunofluorescence and flow cytometry. Sanger sequencing was used to detect the mutation in all hiPSCs. Mitochondrial network morphology analysis was conducted to detect and quantify mitochondrial structures. The mitochondrial respiration ability, glycolytic function, and composite bioenergetics health index (BHI) were measured by the Seahorse Bioscience XFe96 extracellular flux analyzer.
resultsReprogrammed hiPSCs expressed pluripotent stem cell markers including transcription factors POU5F1, NANOG, and SOX2, and cell surface markers SSEA4, TRA-1-60, and TRA-1-81 at the protein level. Sanger sequencing analysis confirmed the presence of mutations in both hiPSCs. Cytogenetic analyses confirmed the presence of normal karyotypes in both hiPSCs. Mitochondrial morphological analysis indicates the presence of hyperfused mitochondria in diseased hiPSC lines. The composite BHI values, a measure of mitochondrial dysfunction that was based on comprehensive bioenergetics analysis of OXPHOS and glycolysis, demonstrated that the mitochondrial functional defects were severe in both the hiPSC lines exhibiting tRNA mutations.
conclusionOverall, the hiPSCs exhibited variable mitochondrial morphology and respiratory dysfunction that have the potential to alter hiPSC differentiation potential, cell fate, and tissue development. These results indicate the potential significance of using hiPSCs and their derivatives to assess mitochondrial morphology and key bioenergetics parameters as a means to better understand early developmental defects in mitochondrial disorders in children.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.